CTLA4 and hepatocellular carcinoma: The efficacy of targeting CTLA-4 and PD-1 was shown by the CHECKMATE-040 study, demonstrating that ipilimumab plus nivolumab could induce durable responses in a subset of patients with HCC previously treated with sorafenib (4, 5, 12).